Search





Search





Markets
/
Stocks
/
lung
/

Pulmonx Corp

LUNG

Add to Watchlist

1.630USD

+0.020+1.24%

Close 07-31 16:00（ET）Quotes delayed by 15 min

67.93MMarket Cap

LossP/E TTM

Pulmonx Corp

1.630

+0.020+1.24%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+1.24%

5 Days

+39.32%

1 Month

+10.88%

6 Months

-0.61%

Year to Date

-26.24%

1 Year

+1.24%

Key Figures

1.600Open

1.850High

1.68MVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

4.04%Turnover Ratio

1.610Prev. Close

1.510Low

1.74MTurnover

LossP/E Static

1.73P/B

0.00%Div Yield TTM

-39.31%ROA

3.88052wk High

1.16Volume Ratio

-56.39MNet Profit

41.67MShares

-1.2916EPS TTM

0.27Beta

-86.22%ROE

1.13052wk Low

21.12%Amplitude

77.97%Gross Margin

67.93MMarket Cap

1.67Reward/Risk

5.25%Risk Rate

TradingKey Stock Score of Pulmonx Corp

Currency: USD Updated: 2026-07-31

Key Insights

Pulmonx Corp's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 76 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.40.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pulmonx Corp's Score

Industry at a Glance

Industry Ranking

76 / 199

Overall Ranking

158 / 4281

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Pulmonx Corp Highlights

StrengthsRisks

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 31.78% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 90.50M.

Overvalued

The company’s latest PE is -1.26, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 36.92M shares, decreasing 13.38% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 83.73K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.68.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.400

Target Price

+172.00%

Upside Space

Pulmonx Corp News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.400

Target Price

+172.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

109

Total

Median

Average

Company name

Ratings

Analysts

Pulmonx Corp

LUNG

Dexcom Inc

DXCM

Stryker Corp

SYK

Medtronic PLC

MDT

Zimmer Biomet Holdings Inc

ZBH

Abbott Laboratories

ABT

...

Indicators

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.053

Neutral

RSI(14)

64.629

Neutral

STOCH(KDJ)(9,3,3)

56.136

Buy

ATR(14)

0.140

High Vlolatility

CCI(14)

160.163

Buy

Williams %R

32.353

Buy

TRIX(12,20)

-0.290

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.392

Buy

MA10

1.318

Buy

MA20

1.394

Buy

MA50

1.421

Buy

MA100

1.395

Buy

MA200

1.610

Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Pulmonx Corp Info

Ticker SymbolLUNG

CompanyPulmonx Corp

CEOFrench (Glendon E)

Websitehttps://pulmonx.com/

Shareholders

Shareholders

Proportion

PRIMECAP Management Company

11.19%

Morgan Stanley & Co. LLC

9.21%

Soleus Capital Management, L.P.

6.31%

BlackRock Institutional Trust Company, N.A.

5.82%

ExodusPoint Capital Management, LP

4.62%

Other

62.86%

Popular Instruments

FAQs

What is the current price of Pulmonx Corp (LUNG)?



The current price of Pulmonx Corp (LUNG) is 1.63.

What is the symbol of Pulmonx Corp?



The ticker symbol of Pulmonx Corp is LUNG.

What is the 52-week high of Pulmonx Corp?



The 52-week high of Pulmonx Corp is 3.88.

What is the 52-week low of Pulmonx Corp?



The 52-week low of Pulmonx Corp is 1.13.

What is the market capitalization of Pulmonx Corp?



The market capitalization of Pulmonx Corp is 67.93M.

Is Pulmonx Corp (LUNG) currently rated as Buy, Hold, or Sell?



According to analysts, Pulmonx Corp (LUNG) has an overall rating of Buy, with a price target of 3.40.

What is the Earnings Per Share (EPS TTM) of Pulmonx Corp (LUNG)?



The Earnings Per Share (EPS TTM) of Pulmonx Corp (LUNG) is -1.33.